

University of Groningen

Noradrenergic and dopaminergic therapy in Parkinson's disease

Verhagen-Kamerbeek, Wilma Dianne Johanna

IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.

Document Version

Publisher's PDF, also known as Version of record

Publication date:

1994

[Link to publication in University of Groningen/UMCG research database](#)

Citation for published version (APA):

Verhagen-Kamerbeek, W. D. J. (1994). *Noradrenergic and dopaminergic therapy in Parkinson's disease: preclinical studies on L-threo-DOPS, decarboxylase inhibitors and transdermal lisuride*. s.n.

Copyright

Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

The publication may also be distributed here under the terms of Article 25fa of the Dutch Copyright Act, indicated by the "Taverne" license. More information can be found on the University of Groningen website: <https://www.rug.nl/library/open-access/self-archiving-pure/taverne-amendment>.

Take-down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Downloaded from the University of Groningen/UMCG research database (Pure): <http://www.rug.nl/research/portal>. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.

List of Publications

Papers

JA Den Boer, HGM Westenberg, WDJ Kamerbeek, WMA Verhoeven, RS Kahn (1987) Effect of serotonin inhibitors in anxiety disorders; a double-blind comparison of clomipramine and fluvoxamine. *Int Clin Psychopharm* 2: 21-32

RS Kahn, HGM Westenberg, WMA Verhoeven, CC Gispen-de Wied, WDJ Kamerbeek (1987) Effect of a serotonin precursor and uptake inhibitor in anxiety disorders: a double blind comparison of 5-hydroxytryptophan, clomipramine and placebo. *Int Clin Psychopharm* 2: 33-45

WDJ Verhagen-Kamerbeek, IP Kema, FAJ Muskiet, AW Teelken, JPWF Lakke (1989) Metabolisme van D,L-threo-DOPS, een niet fysiologische precursor van noradrenaline, en de ziekte van Parkinson. *Tijdschrift NVKC* 14: 178-179

WDJ Verhagen-Kamerbeek, JRA De Haas, AW Teelken, JPWF Lakke (1991) In vivo assessment of the efficacy of L-threo-DOPS in producing extracellular noradrenaline in the CNS of the rat. In: Rollema H, Westerink BHC, Drijfhout WJ (eds) *Monitoring Molecules in Neuroscience*, Univ Centre for Pharmacy, Groningen, The Netherlands, 373-376

WDJ Verhagen-Kamerbeek, JRA De Haas, AW Teelken, JPWF Lakke (1991) The effects of the selective noradrenergic neurotoxin DSP-4 on the central noradrenergic and dopaminergic system of the rat: a microdialysis study. In: Rollema H, Westerink BHC, Drijfhout WJ (eds) *Monitoring Molecules in Neuroscience*, Univ Centre for Pharmacy, Groningen, The Netherlands, 409-412

WDJ Verhagen-Kamerbeek, JPWF Lakke (1992) Effects of peripheral decarboxylase inhibitors on central dopamine synthesis. *New Trends Clin Neuropharm* VI: 69-72

WDJ Verhagen-Kamerbeek, JRA De Haas, AW Teelken, JPWF Lakke (1993) In vivo microdialysis studies on the role of L-threo-DOPS in the treatment of Parkinson's disease. In: Narabayashi H, Mizuno Y (eds) *Norepinephrine deficiency and its treatment with L-threo-DOPS in Parkinson's disease and the related disorders*, The Parthenon Publishing Group, Carnforth, UK, 49-58

WDJ Verhagen-Kamerbeek, I Hazemeijer, J Korf, JPWF Lakke (1993) Attenuation of haloperidol-induced catalepsy by noradrenaline and L-threo-DOPS. *J Neural Transm [P-D Sect]* 6: 17-26

BG Wolthers, WDJ Verhagen-Kamerbeek, CM van Beusekom, F Elshof, AW de Ruyter-Buitenhuis, ERP Brunt, JPWF Lakke (1993) Quantitative determination of the dopamine agonist lisuride in plasma using high performance liquid chromatography with fluorescence detection. *J Chromat* 622: 33-38

IP Kema, WDJ Verhagen-Kamerbeek, FAJ Muskiet, AW Teelken, JPWF Lakke (1994) Metabolism of the synthetic noradrenaline precursor L-threo-3,4-dihydroxyphenylserine (L-threo-DOPS) with and without carbidopa in rats. Comparison with L-DOPA and D-threo-DOPS. (Submitted)

WDJ Verhagen-Kamerbeek, G Luurtsema, PJ Swart, A de Ruiter, BG Wolthers, E Brunt, RA de Zeeuw, AW Teelken, JPWF Lakke (1995) Transdermal application: a mode of dopaminergic treatment of Parkinson's disease. Effects of the D₂-agonist lisuride in rats and human volunteers. (in preparation)

Abstracts

JA Den Boer, HGM Westenberg, CC Gispen-de Wied, WDJ Kamerbeek, RS Kahn (1986) Treatment of anxiety disorders with clomipramine and fluvoxamine: a double-blind study. Proc 27th Dutch Fed Meeting, 46

JA Den Boer, HGM Westenberg, WDJ Kamerbeek, B Mastebroek (1987) Lactate infusion as a biological marker of panic attacks. Proc 28th Dutch Fed Meeting, 55

WDJ Verhagen-Kamerbeek, JT Geradts, AW Teelken, JPWF Lakke (1989) Central noradrenergic function of L-3,4-dihydroxyphenylserine (DOPS) as assessed with on-line in vivo transcerebral microdialysis. J Neurosci Methods 29: 278

WDJ Verhagen-Kamerbeek, JCVM Copray, GJ Ter Horst, PA Kelders, AW Teelken, JPWF Lakke (1990) Effect of L-3,4-dihydroxyphenylserine (DOPS) and benserazide on extracellular noradrenaline in rat frontal cortex, studied with on-line microdialysis. Eur J Neurosci Suppl 3: 229

G Luurtsema, WDJ Verhagen-Kamerbeek, AW Teelken, JPWF Lakke (1990) Transdermal application: a mode of dopaminergic treatment of Parkinson's disease. Effects of the D₂-agonist lisuride measured by intracerebral microdialysis in the rat. New Trends Clin Neuropharm IV: 114

WDJ Verhagen-Kamerbeek, JRA De Haas, JPWF Lakke (1991) Monitoring of striatal dopamine metabolism in response to L-threo-DOPS with and without a peripheral decarboxylase inhibitor. Proc 32nd Dutch Fed Meeting, 194

WDJ Verhagen-Kamerbeek, JCVM Copray, G Luurtsema, JRA De Haas, JPWF Lakke (1991) Transdermal delivery of D₂-agonist lisuride monitored by extracellular striatal dopamine, measured with microdialysis. Current Separations 10 (3): 103-104

WDJ Verhagen-Kamerbeek, JRA De Haas, AW Teelken, JPWF Lakke (1991) In vivo microdialysis studies on the role of L-threo-DOPS in the treatment of Parkinson's disease. Proc Int Symp Norepinephrine deficiency and its treatment with L-threo-DOPS in Parkinson's disease and the related disorders, Tokyo, Japan, 16

WDJ Verhagen-Kamerbeek, R van der Geize, JPWF Lakke (1992) Potential of L-threo-DOPS as a precursor of central nervous noradrenaline quantified by in vitro microdialysis. Proc 33rd Dutch Fed Meeting, 112

WDJ Verhagen-Kamerbeek, I Hazemeijer, JPWF Lakke (1992) Reversal of haloperidol-induced catalepsy by noradrenaline and L-threo-DOPS. Proc 33rd Dutch Fed Meeting, 111

WDJ Verhagen-Kamerbeek, I Hazemeijer, J Korf, JPWF Lakke (1992) Noradrenaline precursor L-threo-DOPS attenuates haloperidol-induced akinesia. Proc Int Symp Noradrenergic Mechanisms in Parkinson's Disease, Castres, France, 24 P6

IP Kema, WDJ Verhagen-Kamerbeek, FAJ Muskiet, AW Teelken, JPWF Lakke (1993) Metabolism of synthetic noradrenaline precursor L-threo-3,4-dihydroxyphenylserine (L-threo-DOPS) with and without carbidopa in rats. Comparison with L-DOPA and D-threo-DOPS. Spring Meeting of the Groningen Institute for Drug Studies. No 7

WDJ Verhagen-Kamerbeek (1993) Op weg naar nieuwe medicatie bij de ziekte van Parkinson. In: Parkinson, een bewogen ziektebeeld. Duphar Nederland BV, 18-19